N. Anderson

630 total citations
19 papers, 473 citations indexed

About

N. Anderson is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, N. Anderson has authored 19 papers receiving a total of 473 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in N. Anderson's work include Neuroendocrine Tumor Research Advances (4 papers), Neutropenia and Cancer Infections (4 papers) and Chemotherapy-induced organ toxicity mitigation (4 papers). N. Anderson is often cited by papers focused on Neuroendocrine Tumor Research Advances (4 papers), Neutropenia and Cancer Infections (4 papers) and Chemotherapy-induced organ toxicity mitigation (4 papers). N. Anderson collaborates with scholars based in United States and Australia. N. Anderson's co-authors include Jacob J. Lokich, Murray M. Bern, H S Garewal, Rudolph M. Navari, Stefan Madajewicz, Thomas Beck, Barry Greenberg, Karen Caldwell, N. Simon Tchekmedyian and A. Y. Chang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

N. Anderson

16 papers receiving 437 citations

Peers

N. Anderson

ONCOL

SURGE

PRM

PFM

C. Sessa Switzerland

J. Shapira Israel

M. Berman United States

Roberto Valenza Italy

Leung Li Hong Kong

Vinicio Fosser Italy

Yingwei Qi United States

K. Buser Switzerland

Y. Kenis Belgium

Suzanne M. Fields United States

C. Sessa Switzerland

N. Anderson

203 ×0.8

ONCOL

106 ×0.7

SURGE

122 ×1.2

91 ×0.9

PRM

31 ×0.5

PFM

Citations per year, relative to N. Anderson N. Anderson (= 1×) peers C. Sessa

Countries citing papers authored by N. Anderson

Since Specialization

Citations

This map shows the geographic impact of N. Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Anderson more than expected).

Fields of papers citing papers by N. Anderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Anderson. The network helps show where N. Anderson may publish in the future.

Co-authorship network of co-authors of N. Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of N. Anderson. A scholar is included among the top collaborators of N. Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Anderson. N. Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Anderson, N., Sharmila Dorbala, & Peter Mollee. (2025). Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis. Blood. 146(10). 1157–1162.

Gibbons, A.J., N. Anderson, Fiona Kwok, et al.. (2023). Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy. Blood. 142(Supplement 1). 2030–2030. 1 indexed citations

Anderson, N. & Steven Lane. (2022). Eltrombopag in Frontline Therapy for Severe Aplastic Anemia: A RACE Against Time. The Hematologist. 19(3). 1 indexed citations

Lokich, J, et al.. (1998). Phase I–II trial of 14 day infusional 6-Mercaptopurine in advanced colorectal cancer. European Journal of Cancer. 34(4). 584–585. 2 indexed citations

Lokich, Jacob J., et al.. (1998). Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer. European Journal of Cancer. 34(5). 659–663. 9 indexed citations

Lokich, Jacob J. & N. Anderson. (1998). Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Annals of Oncology. 9(1). 13–21. 233 indexed citations

Lokich, Jacob J., et al.. (1998). Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas. European Journal of Cancer. 34(5). 664–667. 11 indexed citations

Lokich, Jacob J. & N. Anderson. (1997). Dose intensity for bolus versus infusion chemotherapy administration: Review of the literature for 27 anti-neoplastic agents. Annals of Oncology. 8(1). 15–25. 29 indexed citations

Lokich, J, et al.. (1996). Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).. PubMed. 6(1). 39–42.

10.

Navari, Rudolph M., Stefan Madajewicz, N. Anderson, et al.. (1995). Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.. Journal of Clinical Oncology. 13(9). 2408–2416. 68 indexed citations

11.

Lokich, Jacob J., et al.. (1995). Multi-day fractionated administration schedule for paclitaxel. Annals of Oncology. 6(9). 883–885. 6 indexed citations

12.

Anderson, N., et al.. (1992). Etoposide Plus Carboplatin Admixture Phase I Study of Five- or Seven-Day Continuous Infusion. American Journal of Clinical Oncology. 15(4). 314–318. 2 indexed citations

13.

Anderson, N., et al.. (1992). Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons.. PubMed. 70(4 Suppl). 998–1002. 36 indexed citations

14.

Lokich, Jacob J., et al.. (1991). Infusion of floxuridine plus etoposide plus cisplatin in human malignancies. European Journal of Cancer and Clinical Oncology. 27(12). 1593–1596. 4 indexed citations

15.

Lokich, Jacob J., et al.. (1991). Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial. Cancer. 68(4). 744–746. 11 indexed citations

16.

Lokich, Jacob J., et al.. (1991). Infusional carboplatin. Phase I studies of 5-day and 14-day infusions. Cancer. 68(1). 68–71. 6 indexed citations

17.

Lokich, Jacob J., et al.. (1991). Ifosfamide continuous infusion without mesna. A phase I trial of a 14‐day cycle. Cancer. 67(4). 883–885. 14 indexed citations

18.

Anderson, N., et al.. (1989). A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Demonstration of biochemical modulation. Cancer. 63(2). 233–237. 29 indexed citations

19.

Lokich, Jacob J., et al.. (1980). Pancreatic alpha cell tumors: Case report and review of the literature. Cancer. 45(10). 2675–2683. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact